Page 70 - Clinical Development News Today

Former officials at the FDA responsible for reviewing safety and efficacy data on new drugs and vaccines went on to work for highly profitable companies making those products.

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses and 31% disease control rate across all dose levels in a range of solid tumor types, including...

MORRISVILLE, N.C.- November 3, 2023 - Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, has signed an agreement with P3 Research Ltd Network. The...

A not-for-profit organization, Medicines Development for Global Health (MDGH), that develops medicines for neglected diseases in low- and middle-income countries, will benefit from support from contract research organization (CRO), Phastar.

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Desig...

02.11.2023 - PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ... Seite 1

More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that using two tests can help detect it. That's why Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the ...

New real-world evidence and application of cutting-edge AI technology underscore PharmaEssentia commitment to improving outcomes for MPN patients ...

The US Food and Drug Administration (FDA) has approved a potassium-competitive acid blocker (PCAB) as a new treatment for the healing of all grades of erosive esophagitis.

The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.